翰森製藥(03692.HK):國內首個注射用福沙匹坦雙葡甲胺獲批上市
格隆匯10月16日丨翰森製藥(03692.HK)宣佈,由公司附屬公司江蘇豪森藥業集團有限公司開發的“注射用福沙匹坦雙葡甲胺”(商品名稱“坦能”)已獲中華人民共和國國家藥品監督管理局頒發藥品註冊批件,獲批上市。
作為臨牀急需藥,福沙匹坦雙葡甲胺已被列入中國《第一批鼓勵仿製藥品目錄》中。坦能為國內首個及目前唯一獲批上市的福沙匹坦雙葡甲胺,按照化藥新3類申報,視同通過一致性評價。
坦能用於預防化療引起的急性和延遲性惡心嘔吐,其獲批上市將進一步豐富和完善集團的抗腫瘤產品線佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.